Amyloid‐β oligomers (AβO) are causally related to Alzheimer's disease (AD). Dietary natural compounds, especially flavonoids and flavan‐3‐ols, hold great promise as potential AD‐preventive agents but their host and gut microbiota metabolism complicates identification of the most relevant bioactive species. This study aims to investigate the ability of a comprehensive set of phenyl‐γ‐valerolactones (PVL), the main circulating metabolites of flavan‐3‐ols and related dietary compounds in humans, to prevent AβO‐mediated toxicity.
Amyloid‐β oligomers (AβO) are causally related to Alzheimer's disease (AD). Dietary natural compounds, especially flavonoids and flavan‐3‐ols, hold great promise as potential AD‐preventive agents but their host and gut microbiota metabolism complicates identification of the most relevant bioactive species. This study aims to investigate the ability of a comprehensive set of phenyl‐γ‐valerolactones (PVL), the main circulating metabolites of flavan‐3‐ols and related dietary compounds in humans, to prevent AβO‐mediated toxicity.
